The time seems right to consider DCIS subtype-dependent treatment, comprising appropriate local treatment for HER2-positive DCIS patients and de-escalation for hormone receptor-positive, HER2-negative DCIS patients. This evidence concerns the gene NR4A1 and ductal breast carcinoma in situ.